|
Urogen Pharma Ltd. (URGN) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
UroGen Pharma Ltd. (URGN) Bundle
Gewinnen Sie einen Einblick in Ihre Urogen Pharma Ltd. (URGN) -bewertungsanalyse mit unserem ausgefeilten DCF -Taschenrechner! Diese Excel -Vorlage mit realen URGN -Daten ermöglicht es Ihnen, Prognosen und Annahmen anzupassen, um den inneren Wert von Urogen Pharma mit Genauigkeit zu bestimmen.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | 11.8 | 48.0 | 64.4 | 82.7 | 137.0 | 226.9 | 375.8 | 622.3 | 1,030.7 |
| Revenue Growth, % | 0 | 65450 | 307.17 | 33.96 | 28.52 | 65.62 | 65.62 | 65.62 | 65.62 | 65.62 |
| EBITDA | -108.2 | -122.7 | -90.2 | -78.0 | -63.8 | -130.7 | -216.5 | -358.6 | -593.9 | -983.7 |
| EBITDA, % | -600855.56 | -1039.99 | -187.66 | -121.25 | -77.17 | -95.43 | -95.43 | -95.43 | -95.43 | -95.43 |
| Depreciation | 1.3 | 2.0 | 1.8 | 1.8 | 1.7 | 34.5 | 57.1 | 94.6 | 156.7 | 259.5 |
| Depreciation, % | 7355.56 | 17.32 | 3.69 | 2.82 | 2.06 | 25.18 | 25.18 | 25.18 | 25.18 | 25.18 |
| EBIT | -109.5 | -124.8 | -91.9 | -79.8 | -65.5 | -131.3 | -217.5 | -360.2 | -596.5 | -987.9 |
| EBIT, % | -608211.11 | -1057.32 | -191.35 | -124.07 | -79.23 | -95.85 | -95.85 | -95.85 | -95.85 | -95.85 |
| Total Cash | 147.1 | 103.9 | 89.8 | 100.0 | 137.0 | 137.0 | 226.9 | 375.8 | 622.3 | 1,030.7 |
| Total Cash, percent | .8 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | 7.0 | 11.7 | 12.7 | 15.4 | 33.6 | 55.6 | 92.1 | 152.5 | 252.6 |
| Account Receivables, % | 0 | 59.73 | 24.39 | 19.74 | 18.67 | 24.5 | 24.5 | 24.5 | 24.5 | 24.5 |
| Inventories | .0 | 2.0 | 4.8 | 4.3 | 5.7 | 11.0 | 18.3 | 30.3 | 50.1 | 83.0 |
| Inventories, % | 0 | 16.65 | 10.06 | 6.72 | 6.86 | 8.06 | 8.06 | 8.06 | 8.06 | 8.06 |
| Accounts Payable | 4.7 | 3.3 | 5.8 | 5.5 | 6.5 | 42.8 | 70.9 | 117.4 | 194.5 | 322.1 |
| Accounts Payable, % | 26077.78 | 27.72 | 12.04 | 8.59 | 7.88 | 31.25 | 31.25 | 31.25 | 31.25 | 31.25 |
| Capital Expenditure | -.3 | -1.2 | -.8 | -.3 | -.2 | -30.8 | -51.0 | -84.5 | -140.0 | -231.9 |
| Capital Expenditure, % | -1805.56 | -10.3 | -1.57 | -0.39467 | -0.23455 | -22.5 | -22.5 | -22.5 | -22.5 | -22.5 |
| Tax Rate, % | -3.99 | -3.99 | -3.99 | -3.99 | -3.99 | -3.99 | -3.99 | -3.99 | -3.99 | -3.99 |
| EBITAT | -104.7 | -128.1 | -93.1 | -80.7 | -68.1 | -130.1 | -215.6 | -357.0 | -591.3 | -979.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -99.0 | -137.7 | -97.1 | -79.9 | -69.7 | -113.7 | -210.6 | -348.9 | -577.8 | -957.0 |
| WACC, % | 10.47 | 10.65 | 10.65 | 10.65 | 10.65 | 10.61 | 10.61 | 10.61 | 10.61 | 10.61 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1,496.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -976 | |||||||||
| Terminal Value | -11,333 | |||||||||
| Present Terminal Value | -6,844 | |||||||||
| Enterprise Value | -8,340 | |||||||||
| Net Debt | 4 | |||||||||
| Equity Value | -8,345 | |||||||||
| Diluted Shares Outstanding, MM | 29 | |||||||||
| Equity Value Per Share | -289.40 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real UroGen Pharma Ltd. (URGN) financials.
- Real-World Data: Historical data and forward-looking estimates (highlighted in the yellow cells).
- Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Instantly observe the effects of your inputs on UroGen Pharma Ltd. (URGN)'s valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- Comprehensive UroGen Financial Data: Access reliable pre-loaded historical figures and future forecasts.
- Tailorable Projection Inputs: Modify highlighted cells for metrics such as WACC, growth rates, and profit margins.
- Real-Time Calculations: Instant updates for DCF, Net Present Value (NPV), and cash flow assessments.
- Interactive Visualization Dashboard: User-friendly charts and summaries to illustrate your valuation findings.
- Designed for All Skill Levels: An intuitive layout suitable for investors, CFOs, and consultants alike.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered UroGen Pharma data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for UroGen Pharma’s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for UroGen Pharma Ltd. (URGN)?
- Accurate Data: Utilize real UroGen Pharma financials for dependable valuation outcomes.
- Customizable: Tailor essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-configured calculations save you the hassle of starting from the ground up.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants in the pharmaceutical sector.
- User-Friendly: Designed with an intuitive interface and step-by-step guidance for ease of use by all.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling UroGen Pharma Ltd. (URGN) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models for UroGen Pharma Ltd. (URGN).
- Consultants: Deliver professional valuation insights on UroGen Pharma Ltd. (URGN) to clients quickly and accurately.
- Business Owners: Understand how biotech companies like UroGen Pharma Ltd. (URGN) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to UroGen Pharma Ltd. (URGN).
What the UroGen Pharma Ltd. (URGN) Template Contains
- Comprehensive DCF Model: Editable template with detailed valuation calculations tailored for UroGen Pharma Ltd. (URGN).
- Real-World Data: UroGen Pharma Ltd. (URGN)’s historical and projected financials preloaded for analysis.
- Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Full annual and quarterly breakdowns for in-depth insights into UroGen Pharma Ltd. (URGN).
- Key Ratios: Built-in analysis for profitability, efficiency, and leverage specific to UroGen Pharma Ltd. (URGN).
- Dashboard with Visual Outputs: Charts and tables providing clear, actionable results for stakeholders of UroGen Pharma Ltd. (URGN).
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.